NT-proBNP

Soon on turbidimetric analysers - Pre-Launch

NT-proBNP immunoassay soon on clinical chemistry platforms

NT-proBNP remains a cornerstone in heart failure diagnostics, and is used for management of heart failure patients.1 However, diagnostic confidence can be limited due to endogenous  glycosylation of the NT-proBNP molecule, especially in underserved patient subgroups. Current commercial assays tend to underestimate NT-proBNP levels due to glycosylation at antibody binding sites.2-5

Gentian is developing a glycosylation-independent NT-proBNP assay that aims to improve diagnostic consistency and expand access to high-quality diagnostics.  

Gentian’s proprietary antibody and nanoparticle-based technology will allow for comparable, consistent, biotin interference-free measurement of clinically relevant concentrations of NT-proBNP. Moving NT-proBNP to fast, cost-effective, high-volume and easily accessible clinical chemistry analysers can generate laboratory productivity gain:

Glycosylation-independent accuracy: Provides consistent results

No biotin interference: Reliable results free from biotin interference

Seamless integration: Designed for open-access clinical chemistry platforms

for-web_man-blodtest-400x400_web-ready

Collaborating toward better outcomes 

We are engaging with clinicians, laboratories and IVD partners 
to support: 

  • Evidence generation in real-world settings 
  • Clinical validation and implementation 
  • Market introduction 

Get in touch now

Biotin interference-free

The Gentian NT-proBNP assay has no biotin interference. The Gentian assay, contrary to many commercially available NT-proBNP assays, is not using biotinylated antibodies in the manufacturing process. 

The challenge with biotin interference in routine clinical immunoassays has increased owing to the rising popularity of biotin as a dietary supplement and its pharmacologic use for selected patient populations.

NT-proBNP-400x400-web-ready
patient-bed-_heart-blood-test-instr_400x400

BNP vs NT-proBNP

Although both BNP and NT-proBNP have similar uses in the clinic, the molecules cannot be directly compared. BNP is the bioactive peptide and has a half-life of approximately 20 minutes, whereas NT-proBNP is biologically inactive and has a half-life of 1-2 hours. The concentration of NT-proBNP in blood is thus higher than the concentration of BNP. BNP is eliminated by contact with receptors in the liver, lung, kidney, and vascular endothelium and by the kidney. In contrast, NT-proBNP is only cleared by the kidneys and the elimination is therefore highly dependent on kidney function compared to BNP6. NT-proBNP is more stable in vitro than BNP.

CTA(27)
 

Collaborating toward better outcomes - Contact us for early adoption program 

Would you like to know more about our NT-proBNP immunoassay? 

Let us know if you are interested in OEM or distribution opportunities, or to validate the assay in your lab at the time of launch. Please send us an email to marketing@gentian.com or fill out the form below and our Product Manager for NT-proBNP will get in touch.

 

CTA(28)

Frequently asked questions

Will the Gentian NT-proBNP Immunoassay be available on all clinical chemistry analysers?

The Gentian NT-proBNP assay is an open channel immunoassay, and  can run on most clinical chemistry analysers, independent of the platform provider

Please contact marketing@gentian.com for more information on availability on the clinical analyser in your laboratory and future validations. 

What is the assay principle of Gentian's NT-proBNP?

Gentian's NT-proBNP assay will be the first and only Particle-Enhanced Turbidimetric Immunoassay (PETIA) on multiple platforms for in vitro diagnostic testing of NT-proBNP.

References:

  1. Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016.
  2. Hammerer-Lercher A, et al. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem. 2008
  3. Halfinger B, et al. Unraveling the Molecular Complexity of O-Glycosylated Endogenous (N-Terminal) pro-B-Type Natriuretic Peptide Forms in Blood Plasma of Patients with Severe Heart Failure. Clin Chem. 2017
  4. Røsjø H et al. Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the Akershus Cardiac Examination 2 Study. Clin Chem. 2015
  5. Nishikimi T et al. The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart. 2012
  6. Srisawasdi P et al. The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. Am J Clin Pathol. 2010